Scott Kuennen, MD
Family Medicine · Kansas City, MONPI 1972560324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Pfizer at 29.2% of the total. Reporting peaked in 2019 at $609 and has fallen 56.6% since, to $264 in 2025.
Across 104 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$469
- AstraZeneca$304
- AbbVie$203
- Boehringer Ingelheim$83
- Novo Nordisk$69
- GSK$61
- plus $418 from 14 others
Across 157 payments — averaging $14,206 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$750K
- AstraZeneca$524K
- Bavarian Nordic A/s$515K
- Genentech, Inc.$340K
- Currax Pharmaceuticals LLC$83K
- Pfizer$17K
What the payments were for
- Food & beverage$1,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 46 | $469 |
| AstraZeneca | 7 | $304 |
| AbbVie | 11 | $203 |
| Boehringer Ingelheim | 5 | $83 |
| Novo Nordisk | 4 | $69 |
| GSK | 4 | $61 |
| Nevro Corp. | 2 | $56 |
| Amgen | 4 | $55 |
| Abbott | 3 | $54 |
| Lilly USA, LLC | 4 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Boston Scientific | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Recor Medical Inc | 1 | $22 |
| Vertex | 1 | $19 |
| Antares Pharma, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,609 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 180 | $231,005 |
| OzempicSemaglutide | 141 | $175,254 |
| EliquisApixaban | 153 | $142,227 |
| MounjaroTirzepatide | 65 | $92,459 |
| FarxigaDapagliflozin Propanediol | 74 | $81,292 |
| TrulicityDulaglutide | 49 | $54,944 |
| JanuviaSitagliptin Phosphate | 49 | $48,231 |
| RybelsusSemaglutide | 18 | $39,591 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $24,013 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,760 |
| XareltoRivaroxaban | 17 | $20,405 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 37 | $10,284 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,669 |
| Atorvastatin Calcium | 777 | $8,550 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 23 | $6,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $83 | $231,005180 claims |
| Novo NordiskOzempic, Rybelsus | $69 | $214,845159 claims |
| PfizerEliquis, Abrysvo | $469 | $149,158176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $147,403114 claims |
| AstraZenecaFarxiga, Symbicort | $304 | $88,21988 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta | $61 | $47,28693 claims |
| AbbVieSynthroid | $203 | $3,44654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Kansas City
- Blair ThedingerKansas City$71K
- Jon MattsonKansas City$53K
- Meredith LevineKansas City$26K
- Kelly SandriKansas City$17K
- Michael SimanovskyKansas City$16K
- Teresa MarshallKansas City$16K
- Nora GomezKansas City$15K
- Julie AlvarezKansas City$15K
- Neal MooreKansas City$14K
- Stephen AdamsSpringfield$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.